Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia

Telavancin is a fairly novel antibiotic derived from vancomycin developed to combat the constant evolutionary war against bacteria. It has achieved high clinical success in its role in treating Gram-positive organisms, although like in the case of any other antibiotics, failure can arise. The purpose of this article is to describe a case in which telavancin clinically failed in treating persistent methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) bacteremia in a patient while describing the cause that led to telavancin failure.